Trials / Completed

CompletedNCT00161837

Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004

Single-blind Randomized Controlled Phase II/III Study to Investigate the Immunogenicity and Safety of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived) in Comparison to a Licensed Egg-derived Influenza Vaccine for Season 2003/2004

Status: Completed
Phase: Phase 2 / Phase 3
Study type: Interventional
Enrollment: —

Sponsor: Alachua Government Services, Inc. · Industry
Sex: All
Age: 16 Years
Healthy volunteers: Accepted

Summary

The objectives of the study are to assess the immunogenicity and safety of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.

Conditions

Influenza

Interventions

Type	Name	Description
BIOLOGICAL	Vero Cell-derived Influenza Vaccine
BIOLOGICAL	Egg-derived Influenza Vaccine

Timeline

Start date: 2003-12-01
Completion: 2004-07-01
First posted: 2005-09-13
Last updated: 2015-10-09

Locations

1 site across 1 country: Poland

Source: ClinicalTrials.gov record NCT00161837. Inclusion in this directory is not an endorsement.